1st Counsel – Lifestyle
Author:
Capstone Infrastructure Corporation
ICOTYDE™ (icotrokinra) one-year results confirm lasting skin clearance and favorable safety profile in once‑daily pill for plaque psoriasis
March 30, 2026
FDA approval of ICOTYDE™ (icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide
March 18, 2026
Capstone Infrastructure Corporation Reports Fourth Quarter and Fiscal 2025 Results and Declares a Quarterly Dividend
March 4, 2026